will trump make glp 1 cheaper low-cost GLP-1 plan a likely boost for Eli Lilly, Novo Nordisk Trump announces lower prices for

New approaches are offering hope where traditional methods max out

Personalized medicine in type 2 diabetes: what does the future hold

Injectables generally deliver a faster systemic absorption

From gut microbiota through low-grade inflammation to obesity: Key players and potential targets

It was discovered in 2012,[3] by a team of researchers at Novo Nordisk as a longer-acting alternative to liraglutide.[4] Clinical trials were started in 2015, and phase 3 was completed in 2016.[5] Researchers at the University of Leeds and Novo Nordisk reported in 2017 that it can also be used for the treatment of obesity.[6] It reduces hunger, food craving and body fat.[7] FDA approval was applied in December 2016, and in October 2017 FDA Advisory Committee voted 16-0 in favour.[8] On December 5, 2017, semaglutide was approved by the US FDA

Awards are given in 4 organizational categories: comprehensive academic medical centers